Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Jun 07, 2020 12:41pm

59 Views

Post# 31121724

RE:RE:Isotrention Clinical Trials for Covid Results by August

Doubtful but optimistic that at least sales haven't plummeted. Would be happy if we could continue positive momentum until end of year. Hoping for new revenue from Mexico and Brazil deals and Trevyent at end of the year. Trulance resolution is coming and Bozo is now gone to lick her wounds. She knew this company would erupt but chose a money loosing company to invest in. Sad really

Bullboard Posts

E3 inches closer to Alberta's first lithium production plant